Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.31
-0.0400-2.96%
Volume:656.90K
Turnover:845.91K
Market Cap:92.62M
PE:-0.59
High:1.37
Open:1.36
Low:1.26
Close:1.35
52wk High:3.96
52wk Low:0.8719
Shares:70.70M
Float Shares:57.24M
Volume Ratio:0.46
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2050
EPS(LYR):-3.8339
ROE:-209.00%
ROA:-75.23%
PB:5.93
PE(LYR):-0.34

Loading ...

Biomea Fusion Inc : JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
Nov 17, 2025

Biomea Fusion downgraded to Underweight from Neutral at JPMorgan

TIPRANKS
·
Nov 15, 2025

Biomea Fusion Is Maintained at Buy by Citigroup

Dow Jones
·
Nov 11, 2025

Biomea Fusion Inc. to Present at Jefferies London Healthcare Conference

Reuters
·
Nov 10, 2025

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 05, 2025

Biomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity

Reuters
·
Nov 05, 2025

H.C. Wainwright Sticks to Its Buy Rating for Biomea Fusion (BMEA)

TIPRANKS
·
Nov 05, 2025

Biomea Fusion Inc. Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 05, 2025

Biomea Fusion Q3 EPS $(0.27) Misses $(0.26) Estimate

Benzinga
·
Nov 05, 2025

Biomea Fusion Q3 net loss narrows

Reuters
·
Nov 05, 2025

Biomea Fusion Reports Q3 2025 Results and Extends Cash Runway Into 2027

Reuters
·
Nov 05, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 04, 2025

Biomea Fusion’s BMF-650: A New Hope in Obesity Treatment?

TIPRANKS
·
Nov 01, 2025

Biomea Fusion Unveils Preclinical Data on Oral GLP-1 Agonist and Menin Inhibitor Combination at ObesityWeek 2025

Reuters
·
Oct 30, 2025

Biomea Fusion Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
Oct 28, 2025

Biomea Fusion’s BMF-219 Trial for Type 1 Diabetes: A Terminated Phase 2 Study

TIPRANKS
·
Oct 28, 2025

Biomea Fusion Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 27, 2025

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

GlobeNewswire
·
Oct 27, 2025

Biomea Fusion to Join Citi's SMID Biotech C-Suite Fireside Chat Series

Reuters
·
Oct 22, 2025

Biomea Fusion’s Promising Clinical Trials and Strategic Advancements Drive Buy Rating

TIPRANKS
·
Oct 14, 2025